Who Paid My Doc
Juantia Applewhite
Registered Nurse, Gerontology Wilson, NC Nurse Practitioner
NPI 1598326456 CMS profile 10854382
1804 Forest Hills Rd W, Wilson, NC 27893
General payments
$35
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Juantia Applewhite of Wilson, NC is reported in the CMS Open Payments database as having received $35 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $35 | 1 |
Beside peers
- Juantia Applewhite
- Registered Nurse, Gerontology median
- Middle half of Registered Nurse, Gerontology
- National median
In program year 2025, general payments to Juantia Applewhite were reported at $35. Among 26 Registered Nurse, Gerontology profiles paid that year, the median was $86 and the middle half received between $22 and $262.
Show as a table
| Year | Juantia Applewhite | Registered Nurse, Gerontology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $0 | — | — | $132 |
| 2022 | $0 | — | — | $149 |
| 2023 | $0 | $150 | $31–$382 | $160 |
| 2024 | $0 | $106 | $46–$261 | $164 |
| 2025 | $35 | $86 | $22–$262 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 69 drugsPart D claims
1,957
Drug cost
$137,736
Branded share of claims
21.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Trulicity Dulaglutide | Brand | 32 | $22,004 | |
| Ozempic Semaglutide | Brand | 19 | $21,714 | |
| Eliquis Apixaban | Brand | 68 | $21,258 | |
| Jardiance Empagliflozin | Brand | 48 | $16,314 | |
| Xarelto Rivaroxaban | Brand | 22 | $6,941 | |
| Combivent Respimat Ipratropium/Albuterol Sulfate | Brand | 11 | $6,356 | |
| Gabapentin | Generic | 109 | $2,610 | |
| Clonazepam | Generic | 57 | $1,930 | |
| Potassium Chloride | Generic | 32 | $1,880 | |
| Insulin Lispro Kwikpen U-100 Insulin Lispro | Brand | 31 | $1,778 |
The 10 drugs with the highest cost, of 69 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 476 Part D prescribers listed as Registered Nurse; they describe a distribution and say nothing about conduct.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Registered Nurse, Gerontology in North Carolina
Related records
Registered Nurse, Gerontology in North Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Registered Nurse, Gerontology
Everyone recorded under this specialty, nationwide.
Doctors in North Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.